Most seed rounds that stall are not underpriced — they are under-specified. A raise sized to the ambition asks investors to believe the whole roadmap; one sized to a defined milestone asks them to believe the next eighteen months, which is a materially easier question.
What 'under-specified' looks like in practice
An under-specified seed round is one where the amount raised is derived from a runway target and a burn rate, without a corresponding statement of what the company will have proven by the time the money runs out. The deck describes a five-year vision and asks the investor to fund a slice of it, without specifying which slice, or what evidence of progress that slice will produce.
This is different from being dishonest or unprepared; many founders raise this way because the roadmap is genuinely the plan, and translating it into a milestone-and-evidence structure is an additional step that is easy to skip under time pressure. The result, however, is a round that investors evaluate against the entire roadmap rather than against a bounded, near-term question.
An investor asked to believe a five-year roadmap has many more places to find doubt than an investor asked to believe an eighteen-month milestone, and under-specification is what allows that doubt to spread across the whole story rather than being contained to a single, testable claim.
Choosing the milestone that repricing depends on
The right milestone is the one that, once achieved, changes what a rational investor is willing to pay for the next round: a regulatory clearance, a signed commercial contract, a defined clinical readout, or a proof point that removes a specific, named risk from the pre-money valuation. A milestone that does not change the post-money case for the next round is not worth sizing a raise around, however important it feels operationally.
Founders sometimes choose a milestone because it is achievable rather than because it is repricing, and investors can tell the difference; a milestone chosen for repricing power is usually harder and closer to genuine commercial or clinical risk than one chosen for comfort.
Identifying this milestone requires working with the eventual buyer of the next round in mind, which is a different exercise from listing internal priorities, and it is usually best done before the raise is modelled rather than fitted retrospectively to a number that has already been decided.
Working backwards from the milestone to the number
Once the milestone is fixed, the raise size follows from the cost and time required to reach it, plus a contingency, rather than from a target valuation or a comparable round size seen elsewhere in the market. This produces a number that is smaller in most cases than a roadmap-sized raise, because it excludes activity that does not bear directly on the milestone.
This calculation should be built bottom-up against the specific cost drivers of reaching the milestone, not against a generic monthly burn multiplied by a runway assumption, because the two approaches produce different numbers and only one of them is defensible to a diligent investor.
A pre-money valuation set against this smaller, sharper raise is easier to defend than one set against a large, vaguely justified number, because the investor can trace exactly what the capital buys and what it does not.
Why a smaller round can be the higher-valuation round
A smaller round sized to a near-term, repricing milestone often achieves a higher effective valuation per unit of dilution than a larger round sized to a roadmap, because the investor is being asked to underwrite less uncertainty and can therefore pay more per point of risk removed. This is counterintuitive to founders who equate round size with progress, but the two are not the same measure.
The post-money reached at the milestone, assuming it is hit, then becomes the reference point for a bridge round or a priced Series A, and a milestone-sized seed round makes that future negotiation cleaner because the achievement is unambiguous rather than a matter of interpretation.
Investors who have seen the roadmap-sized alternative in the same sector tend to recognise a milestone-sized raise quickly, and this recognition itself speeds the process, because it removes one of the standard objections before it is raised.
The narrowing conversation with founders
In practice, sizing a round to a milestone starts as a narrowing exercise: a long list of things the company could do with capital is reduced to the smaller set that bears directly on the chosen milestone, and everything else is deferred to a later round or a later conversation. This is often the more uncomfortable part of the process, because it requires founders to set aside genuinely good ideas that do not serve the immediate financing objective.
The output of this narrowing is a use-of-funds statement that maps every dollar to progress towards the milestone, which is a more defensible document in diligence than a use-of-funds statement organised by department or function.
A cap table modelled against this milestone-sized raise, together with the safe or priced-equity terms used to reach it, gives founders and existing investors a clear, shared view of dilution at the point the milestone is hit, rather than an open-ended trajectory tied to the full roadmap.
Filed under
Last reviewed January 2027
Start with the structure, not the pitch.
Tell us the transaction and the timetable. If it is not something we should run, we will say so.